• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by FoxWayne Enterprises Acquisition Corp.

    2/6/23 5:17:14 PM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FOXW alert in real time by email
    15-12G 1 form15-12g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 15

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934.

     

    Commission File Number: 001-39891

     

    FOXWAYNE ENTERPRISES ACQUISITION CORP.

    (Exact name of registrant as specified in its charter)

     

    1 Rockefeller Plaza, Suite 1039

    New York, New York 10020

    (917) 284-8938

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Title of each class

     

    Units, each consisting of one share of Class A Common Stock and one Redeemable Warrant to purchase one share of Class A common stock

     

    Class A Common Stock, par value $0.0001 per share

    Redeemable Warrants, each exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share

     

    (Title of each class of securities covered by this Form)

     

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1) ☒
    Rule 12g-4(a)(2) ☐
    Rule 12h-3(b)(1)(i) ☒
    Rule 12h-3(b)(1)(ii) ☐
    Rule 15d-6 ☐
    Rule 15-22(b) ☐

     

    Approximate number of holders of record as of the certification or notice date: 9

     

     

     

       
     

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, FOXWAYNE ENTERPRISES ACQUISITION CORP. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

    Dated: February 6, 2023

     

    FOXWAYNE ENTERPRISES ACQUISITION CORP.  
         
    By: /s/ Robb Knie  
    Name: Robb Knie  
    Title: Chief Executive Officer  

     

    -2-

     

    Get the next $FOXW alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FOXW

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FOXW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FOXWAYNE ENTERPRISES ACQUISITION CORP. ANNOUNCES CHANGE OF SPECIAL MEETING DATE AND INCREASE IN ITS CONTRIBUTION TO THE TRUST ACCOUNT FOR EXTENSION PROPOSAL

    NEW YORK, Nov. 29, 2022 /PRNewswire/ -- FoxWayne Enterprises Acquisition Corp. ("FoxWayne" or the "Company") (Nasdaq: "FOXW", "FOXWU", "FOXWW") announced today that its special meeting of stockholders (the "Special Meeting") originally scheduled for Wednesday, November 30, 2022, is being postponed to Tuesday December 13, 2022. At the Special Meeting, stockholders will be asked to vote on the following proposals: (1) a proposal to approve an amendment (the "Extension Amendment") to the Company's Second Amended and Restated Certificate of Incorporation to extend the date by which the Company must consummate a business combination for three months, from January 22, 2023 (the "Original Terminati

    11/29/22 5:20:00 PM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Live Streaming Social Entertainment Platform Powering the Creator Economy, Clover Inc., to Merge with Special Purpose Acquisition Company, FoxWayne Enterprises Acquisition Corp., to Become Public Company

    New entity poised to accelerate the development of Clover's next generation platform for live streaming with a suite of new product introductions. Clover has a growing user base of over 9 million with almost 90% of users between 18-39 years old.  Clover is targeting a launch of VR ('Virtual Reality') Dating and VR Live Streaming in Q4 2023. NEW YORK, Sept. 20, 2022 /PRNewswire/ -- Clover Inc. ("Clover" or the "Company"), a highly rated live streaming company focused on Gen Z and Millennial audiences and creators, and FoxWayne Enterprises Acquisition Corp. (NASDAQ: FOXW, FOXWW) ("FoxWayne"), a special purpose acquisition company ("SPAC"), today announced they have entered into a definitive bu

    9/20/22 8:08:00 AM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aerami Therapeutics Holdings, Inc. and FoxWayne Enterprises Acquisition Corp. Mutually Agree to Terminate Business Combination Agreement

    DURHAM, N.C. and NEW YORK, March 4, 2022 /PRNewswire/ -- Aerami Therapeutics Holdings, Inc. ("Aerami"), a biopharmaceutical company focused on developing inhaled therapies to treat severe respiratory and chronic diseases, and FoxWayne Enterprises Acquisition Corp. (NASDAQ:FOXW) ("FoxWayne"), a publicly traded special purpose acquisition company ("SPAC"), announced today that they have mutually agreed to terminate their previously announced business combination agreement, effective immediately. In light of current unfavorable market conditions, Aerami and FoxWayne believe that

    3/4/22 4:30:00 PM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FOXW
    SEC Filings

    View All

    SEC Form 15-12G filed by FoxWayne Enterprises Acquisition Corp.

    15-12G - FoxWayne Enterprises Acquisition Corp. (0001829999) (Filer)

    2/6/23 5:17:14 PM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 25-NSE filed by FoxWayne Enterprises Acquisition Corp.

    25-NSE - FoxWayne Enterprises Acquisition Corp. (0001829999) (Subject)

    1/27/23 4:38:29 PM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 425 filed by FoxWayne Enterprises Acquisition Corp.

    425 - FoxWayne Enterprises Acquisition Corp. (0001829999) (Subject)

    1/24/23 5:27:10 PM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FOXW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by FoxWayne Enterprises Acquisition Corp. (Amendment)

    SC 13G/A - FoxWayne Enterprises Acquisition Corp. (0001829999) (Subject)

    2/13/24 7:35:39 PM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by FoxWayne Enterprises Acquisition Corp. (Amendment)

    SC 13G/A - FoxWayne Enterprises Acquisition Corp. (0001829999) (Subject)

    2/12/24 11:00:29 AM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by FoxWayne Enterprises Acquisition Corp. (Amendment)

    SC 13G/A - FoxWayne Enterprises Acquisition Corp. (0001829999) (Subject)

    3/10/23 4:03:05 PM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care